基于促性腺激素释放激素激动剂的非典型子宫内膜增生与早期子宫内膜癌保留生育功能治疗:多中心、开放标签、随机设计临床试验方案
约4%的女性在40岁前被诊断为子宫内膜癌,多为未生育且有强烈生育意愿者。年轻非典型子宫内膜增生或早期子宫内膜癌患者常采用大剂量口服孕激素保留生育功能,但复发率较高且长期大剂量口服孕激素可能影响卵巢功能并增加体重增加、肝脏问题、凝血及乳腺癌风险。本研究为开放标签、两臂、随机、研究者发起的多中心试验,评估促性腺激素释放激素激动剂联合左炔诺孕酮宫内缓释系统或联合芳香化酶抑制剂(每4周皮下注射促性腺激素释放激素激动剂且每日口服来曲唑2.5 mg)的方案,计划纳入226例受试者按1:1随机分配,主要目标为评估基于促性腺激素释放激素激动剂的再治疗在24周时达到完全缓解的有效性。
要点
- 约4%的女性在40岁前被诊断为子宫内膜癌。
- 计划纳入226例非典型子宫内膜增生或早期子宫内膜癌患者,按1:1随机分配至两组。
- 主要目标为评估基于促性腺激素释放激素激动剂的再治疗在24周时达到完全缓解的有效性。
核心结论
- 支持子宫内膜癌和非典型子宫内膜增生保守治疗的前瞻性证据有限,需要能实现更高完全缓解率且副作用更少的新方法。
- 本试验将评估基于促性腺激素释放激素激动剂的保留生育功能治疗在肥胖女性和复发患者中的有效性,为子宫内膜癌和非典型子宫内膜增生患者提供有前景的替代选择。
研究设计与样本
- 本研究为开放标签、两臂、随机、研究者发起的多中心试验。
- 计划纳入226例受试者,按1:1比例随机分配至两个治疗组。
- 试验方案获北京协和医院机构审查委员会及另外五家机构委员会批准,遵循世界医学会《赫尔辛基宣言》原则和药物临床试验质量管理规范标准。
主要发现
- 主要目标为确定基于促性腺激素释放激素激动剂的再治疗在24周时使非典型子宫内膜增生或子宫内膜癌患者达到完全缓解的有效性。
- 次要目标包括评估治疗后12周的妊娠率、治疗后妊娠结局及复发率。
关键数值与推荐
- 试验组一为促性腺激素释放激素激动剂联合左炔诺孕酮宫内缓释系统。
- 试验组二为促性腺激素释放激素激动剂联合芳香化酶抑制剂,包括每4周皮下注射促性腺激素释放激素激动剂和每日口服来曲唑2.5 mg。
局限性
- 支持子宫内膜癌和非典型子宫内膜增生保守治疗的前瞻性证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Around 4% of women receive an endometrial cancer diagnosis before turning 40, mainly those without prior childbirth experience and a strong desire to preserve their ability to conceive. Consequently, for young patients diagnosed with atypical endometrial hyperplasia (AEH) or early endometrial carcinoma (EC), a fertility-preserving approach employing high-dose oral progesterone has been adopted. However, previous research has shown a notable relapse rate. Furthermore, the extended use of substantial oral progesterone doses may hinder ovarian function and raise the risk of weight gain, liver issues, blood clotting, and breast cancer. We previously assessed the clinical effectiveness and pregnancy outcomes of gonadotropin-releasing hormone agonist (GnRH-a) based re-treatment for women with EC and AEH who did not respond to oral progestin therapy but achieved favorable treatment results and reproductive outcomes. METHODS: This study will be an open-label, two-armed, randomized, investigator-initiated multicenter trial evaluating the combination of GnRH-a with the levonorgestrel-releasing intrauterine system or the combination of GnRH-a with an aromatase inhibitor (comprising a subcutaneous GnRH-a injection every 4 weeks and daily oral letrozole 2.5 mg). A total of 226 participants will be randomly allocated to one of the two treatment groups in a 1:1 ratio. The primary objective is to determine the effectiveness of GnRH-a-based re-treatment in achieving a complete response (CR) at 24 weeks for patients with AEH or EC. Secondary objectives include assessing the pregnancy rate 12 weeks after treatment, as well as post-treatment pregnancy outcomes and the rate of recurrence. ETHICS AND DISSEMINATION: The protocol received approval from the Institutional Review Board of Peking Union Medical College Hospital and from boards at five other institutions. The trial will adhere to the principles outlined in the World Medical Association's Declaration of Helsinki and follow Good Clinical Practice standards. The trial results will be disseminated through publication in a peer-reviewed journal. CONCLUSIONS: Prospective evidence supporting conservative treatment for EC and AEH is limited. There is a need for new approaches that can achieve higher CR rates with fewer side effects. This trial will assess the effectiveness of GnRH-a-based fertility-sparing treatment in obese women and recurrent patients, offering a promising alternative for patients with EC and AEH. TRIAL REGISTRATION NUMBER: Chinese Clinical Trial Registry ChiCTR2200067099. Registered on December 27, 2022.
引用
- Liu Q, Zhou H, Yu M, et al. GnRH-a-based fertility-sparing treatment of atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EC) patients: a multicenter, open-label, randomized designed clinical trial protocol. Trials. 2024. PMID: 39223633. doi:10.1186/s13063-024-08414-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。